Recent Comments

Comment RSS

Gleevec News and Research RSS Feed - Gleevec News and Research

Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

Overview of current CML therapies

18. November 2009 05:59
Research and Markets (http://www.researchandmarkets.com/research/44c77e/chronic_myelogenou) has announced the addition of Decision Resources, Inc.'s new report "Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec" to their offering. [More]

Posted in: Device / Technology News

Tags: , , , , , , , , ,

Asuragen enters into an exclusive agreement with Life Technologies

18. November 2009 04:13
Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Technologies Corporation to develop and distribute worldwide an in-vitro diagnostic test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). [More]

Posted in: Business / Finance | Device / Technology News

Tags: , , , , , , ,

CytRx reports financial results for the three months and nine months ended September 30, 2009

9. November 2009 09:17
CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009. [More]

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

6. November 2009 07:38
ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. [More]

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

3. November 2009 00:22
ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor. [More]

In-depth analysis of regimens and treatment outcomes for AML and ALL

29. October 2009 04:55
Research and Markets (http://www.researchandmarkets.com/research/c7060e/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy" report to their offering. [More]

Posted in: Medical Condition News

Tags: , , , , , , ,

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

20. October 2009 05:40
Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study. [More]

Recently approved Gleevec drug for cancer treatment

19. October 2009 02:00
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia. [More]

AACR to host its first Frontiers in Basic Cancer Research Meeting

12. October 2009 05:14
The American Association for Cancer Research will host its first Frontiers in Basic Cancer Research Meeting in Boston from Oct. 8-11, 2009. The meeting is expected to draw nearly 500 leading scientists to present on high-profile topics like epigenetics, metastasis and systems biology, and create synergies among the many subfields of basic science. [More]

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

7. October 2009 04:41
Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). [More]

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

1. October 2009 06:40
The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition. [More]

Posted in: Device / Technology News

Tags: , , , , , , , ,

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

30. September 2009 02:01
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center. [More]

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

29. September 2009 08:43
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , ,

Winners of Paul Marks Prize 2009

29. September 2009 03:06
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.